aTYR PHARMA INC (ATYR) stock
Close on Nov 13, 2026Market cap $15.33MP/E –Yield –
aTYR PHARMA INC saw revenue fall 19.1% to $190.00K over fiscal 2025. Free cash flow was -$43.86M. At the latest close the market valued the company at $15.33M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $15.33M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.45
- Dividend yield
- –
- Free cash flow yield
- -286.05%
Fundamentals
- Revenue
- $190.00K
- Net income
- -$53.32M
- EPS, diluted
- -$21.93
- Free cash flow
- -$43.86M
- Book value per share
- $13.83
- Diluted shares
- 2M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $6.21
- Open
- $6.24
- Day's range
- $5.96 – $6.54
- Volume
- 38,122
- Average volume (20 days)
- 211,787
- 52-week range
- $0.17 – $44.40
- RSI (14 days)
- 52.8
- Volatility (1 year)
- 26309.1%
- Relative volume
- 0.02×
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ATYR | S&P 500 | Difference | ATYR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2935.8% | -3.0% | +2938.8 pts | ||
| 3 months | +1004.0% | -2.8% | +1006.8 pts | ||
| Year to date | +679.6% | +11.5% | +668.1 pts | ||
| 1 year | +755.8% | +13.5% | +742.3 pts | ||
| 3 years | -86.4% | +77.7% | −164.1 pts | -48.5% | +21.1% |
| 5 years | -98.3% | +72.6% | −170.9 pts | -55.5% | +11.5% |
| 10 years | -99.7% | +308.2% | −407.8 pts | -43.3% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases aTYR PHARMA filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About aTYR PHARMA
Biological Products, (No Diagnostic Substances)
aTyr Pharma, Inc. is a clinical-stage biotechnology company that utilizes evolutionary intelligence to translate tRNA synthetase biology into therapies for fibrosis and inflammation. Its discovery platform identifies signaling pathways driven by domains derived from all twenty tRNA synthetases to unlock potential therapeutic intervention points. The company's lead therapeutic candidate is efzofitimod, a biologic immunomodulator designed to treat interstitial lung diseases such as pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. Additionally, the company develops pipeline candidates including ATYR0101 for fibrotic diseases and ATYR0750 for inflammatory and fibrotic conditions.
Company profile, executives and historyaTYR PHARMA stock: common questions
What is aTYR PHARMA's stock price?
ATYR closed at $6.11 on Nov 13, 2026, down 1.69% on the day. Over the past 52 weeks it traded between $0.17 and $44.40.
What is aTYR PHARMA's market cap?
aTYR PHARMA was worth $15.33M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ATYR's P/E ratio?
aTYR PHARMA lost money over the twelve months to Sep 30, 2026 (diluted EPS -$21.93), so it has no meaningful P/E ratio.
How much revenue does aTYR PHARMA make?
aTYR PHARMA reported revenue of $190.00K for fiscal 2025, down 19.1% from a year earlier.
Does aTYR PHARMA pay a dividend?
No. aTYR PHARMA has not paid a cash dividend over the last twelve months.
When does aTYR PHARMA report earnings next?
aTYR PHARMA is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ATYR stock performed over the past year?
Including dividends, ATYR returned +755.8% over the past year, against +13.5% for the S&P 500.
How many ATYR shares are sold short?
0M shares were sold short at the latest FINRA report, 3302.36% of the float, or 3.4 days of average trading volume.
Who are aTYR PHARMA's competitors?
Companies most similar to aTYR PHARMA by business, industry and size include ARTV, ABPO, IMA, ZIVO, AIM.
See a number that looks wrong?